# Endocrinology Sector

Canonical URL: https://biopharmsignal.com/sector/endocrinology

Endocrinology includes companies working on hormone-related disease, including diabetes, adrenal disorders, thyroid disease, and other metabolic or gland-driven conditions. It is a useful grouping for following companies exposed to chronic hormone-regulated disease categories.

Companies currently grouped under Endocrinology: 6

## Recent Sector News

- 2026-10-06 11:05 EST — VKTX — [Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-initiation-of-vk2735-oral-maintenance-dosing-clini-13c2b80c) — Source: Viking Therapeutics
- 2026-09-30 12:30 EST — NBIX — [Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-research-advancing-understanding-of-prader-wil-3d23c3bd) — Source: Neurocrine Biosciences
- 2026-09-28 20:30 EST — VKTX — [Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-closing-of-concurrent-upsized-offerings-of-common--f83762b6) — Source: Viking Therapeutics
- 2026-09-28 20:05 EST — NBIX — [Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-appoints-eiry-w-roberts-m-d-as-chief-medical-officer-4f17816b) — Source: Neurocrine Biosciences
- 2026-09-24 11:05 EST — VKTX — [Viking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes](https://biopharmsignal.com/news/VKTX/viking-therapeutics-prices-upsized-500-million-offering-of-common-stock-and-conv-5dbcb968) — Source: Viking Therapeutics
- 2026-09-23 20:32 EST — VKTX — [Viking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-proposed-offerings-of-common-stock-and-convertible-f6e90c95) — Source: Viking Therapeutics
- 2026-09-23 12:00 EST — CORT — [Corcept Announces Planned Leadership Transition](https://biopharmsignal.com/news/CORT/corcept-announces-planned-leadership-transition-200a04c5) — Source: Corcept
- 2026-09-22 11:05 EST — VKTX — [Viking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens](https://biopharmsignal.com/news/VKTX/viking-therapeutics-announces-positive-topline-results-from-maintenance-study-of-ee0b3798) — Source: Viking Therapeutics
- 2026-09-18 12:00 EST — CORT — [Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)](https://biopharmsignal.com/news/CORT/corcept-announces-chmp-opinion-recommending-eu-marketing-authorization-for-lifyo-ce826197) — Source: Corcept
- 2026-09-02 20:05 EST — VKTX — [Viking Therapeutics to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-participate-at-upcoming-investor-conferences-effa7fed) — Source: Viking Therapeutics
- 2026-09-02 20:01 EST — NBIX — [Neurocrine Biosciences to Present at Upcoming Investor Conferences in September](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-to-present-at-upcoming-investor-conferences-in-september-1121c550) — Source: Neurocrine Biosciences
- 2026-08-12 12:30 EST — NBIX — [Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-publication-of-kinect-pro-findings-demonstratin-16dc2ddc) — Source: Neurocrine Biosciences
- 2026-08-07 12:30 EST — NBIX — [Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-590bdb3d) — Source: Neurocrine Biosciences
- 2026-08-03 20:05 EST — CRNX — [Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-reports-second-quarter-2026-financial-results-and-prov-88f72dc1) — Source: Crinetics Pharmaceuticals
- 2026-07-30 20:01 EST — NBIX — [Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-reports-second-quarter-2026-financial-results-6237f8ed) — Source: Neurocrine Biosciences
- 2026-07-29 20:05 EST — CORT — [Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CORT/corcept-therapeutics-announces-second-quarter-financial-results-and-provides-cor-8ea3b293) — Source: Corcept
- 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce) — Source: Viking Therapeutics
- 2026-07-23 20:05 EST — NBIX — [Neurocrine Biosciences Announces Key Leadership Hiring, Promotions](https://biopharmsignal.com/news/NBIX/neurocrine-biosciences-announces-key-leadership-hiring-promotions-40b9699b) — Source: Neurocrine Biosciences
- 2026-07-23 11:05 EST — VKTX — [Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors](https://biopharmsignal.com/news/VKTX/viking-therapeutics-appoints-dorothy-gemmell-to-board-of-directors-d154bd33) — Source: Viking Therapeutics
- 2026-07-22 20:05 EST — CORT — [Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call](https://biopharmsignal.com/news/CORT/corcept-therapeutics-to-announce-second-quarter-financial-results-provide-corpor-1db34366) — Source: Corcept

## Companies

- [AMPH](https://biopharmsignal.com/company/AMPH) — Amphastar Pharmaceuticals, Inc.
- [CORT](https://biopharmsignal.com/company/CORT) — Corcept
- [CRNX](https://biopharmsignal.com/company/CRNX) — Crinetics Pharmaceuticals
- [NBIX](https://biopharmsignal.com/company/NBIX) — Neurocrine Biosciences
- [SPRB](https://biopharmsignal.com/company/SPRB) — Spruce Biosciences
- [VKTX](https://biopharmsignal.com/company/VKTX) — Viking Therapeutics